A possible benefit from therapeutic anticoagulation in patients with coronavirus disease 2019: the Dolo hospital experience in Veneto, Italy
Kardiol Pol
.
2020 Sep 25;78(9):919-921.
doi: 10.33963/KP.15489.
Epub 2020 Jul 6.
Authors
Eleonora Secco
1
,
Maria Cristina Pasqualetto
1
,
Tonino Bombardini
2
,
Eugenio Picano
3
,
Fausto Rigo
1
Affiliations
1
Dolo Cardiology, Dolo Hospital, Azienda no. 3 Serenissima, Venice, Italy
2
Faculty of Medicine, University of Banja‑Luka, Clinical Center ofThe Republic of Srpska, Banja‑Luka, Bosnia‑Herzegovina
3
National Research Council, Institute of Clinical Physiology, Biomedicine Department, Pisa, Italy. picano@ifc.cnr.it
PMID:
32628001
DOI:
10.33963/KP.15489
No abstract available
MeSH terms
Aged
Anticoagulants / therapeutic use*
COVID-19
Coronavirus / drug effects*
Coronavirus Infections / drug therapy*
Female
Humans
Italy
Male
Middle Aged
Pandemics
Pneumonia, Viral / drug therapy*
Treatment Outcome
Substances
Anticoagulants